Ignite Creation Date:
2024-05-05 @ 11:59 AM
Last Modification Date:
2024-10-26 @ 9:17 AM
Study NCT ID:
NCT00198237
Status:
COMPLETED
Last Update Posted:
2014-06-03
First Post:
2005-09-15
Brief Title:
Genomic Proteomic Analysis of Docetaxel Capecitabine as Primary Chemo for Stage II-III Breast Cancer
Sponsor:
Indiana University School of Medicine
Organization:
Indiana University
Study Overview
Official Title:
Genomic and Proteomic Analysis of Docetaxel and Capecitabine as Primary Chemotherapy for Stage II-III Breast Cancer
Status:
COMPLETED
Status Verified Date:
2014-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The primary objective of this study is to determine the efficacy toxicity of combined docetaxel capecitabine as primary chemo for subjects w stage II-III breast cancer
Detailed Description:
The primary objective of this study is to determine the efficacy toxicity of combined docetaxel capecitabine as primary chemotherapy for subjects with stage II-III breast cancerSubjects will be randomized into one of two groups Docetaxel followed by four cycles of docetaxel capecitabine vs capecitabine followed by four cycles of docetaxel and capecitabine
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None